Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Melanoma treatment details. Biologic therapy. Chemotherapy. Institute Gustave Roussy, Paris, France

Survival: 13.9 months
Toxicity Grade: 4
Treatments: Biologic therapy
Country: France
City/State/Province: Paris
Hospital: Institute Gustave Roussy
Journal: Link
Date: 6/2013

This phase 2 study involved BRAF-mutant metastatic melanoma patients who were divided into two separate treatment groups. Group A consisted of 45 patients with a median age of 57 years and 49% male. Group B had 46 patients with a median age of 52 years and 61% male.

Patients in group A were treated with the chemotherapy agent dacarbazine and the biologic therapy agent selumetinib, a small molecule inhibitor of MAPK/ERK kinases that interferes with cancer cell growth.
Patients in group B were treated with dacarbazine and a placebo.

The most severe toxicities in group A were of grade 4 and included grade 3-4 neutropenia and diarrhea. Visual disturbances, acne, and peripheral edema (swelling) were also reported.

The most severe toxicities in group B were of grade 4 and included grade 3-4 fatigue, thrombocytopenia, and neutropenia. Nausea, diarrhea, vomiting, and constipation were also reported.

The median overall survival for groups A and B was 13.9 and 10.5 months, respectively.

This study was supported by AstraZeneca.

Correspondence: Dr. Caroline Robert; email:

E-mail to a Friend Email Physician More Information